AD
Therapeutic Areas
Xenon Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Azetukalner (XEN1101) | Focal Onset Seizures | Phase 3 |
| XEN1701 | Pain | Phase 1 |
| XEN1120 | Undisclosed (Kv7 target) | Phase 1 |
Leadership Team at Xenon Pharmaceuticals
IM
Ian Mortimer
President and Chief Executive Officer
DC
Darren Cline
Chief Commercial Officer
JE
James Empfield
Executive Vice President, Drug Discovery
TK
Tucker Kelly
Chief Financial Officer
CK
Chris Kenney
Chief Medical Officer
SM
Shelley McCloskey
Executive Vice President, Human Resources
MD
Matthew D. Ronsheim
Chief Operating Officer
RS
Robin Sherrington
Executive Vice President, Strategy and Innovation